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Malignant pleural mesothelioma is a notoriously chemoresistant tumour. However, a recent single institution study showed an
impressive activity of gemcitabine and cisplatin. Our aim is to investigate the efﬁcacy and toxicity of a gemcitabine and cisplatin
combination in selected and chemo-naive patients with histologically proven malignant pleural mesothelioma. Method:
Gemcitabine 1250 mg m
72 was administered on day 1 and day 8 and cisplatin 80 mg m
72 was administered on day 1 in a 3-
week cycle with a maximum of six cycles. Response and toxicity evaluations were performed according to WHO and NCIC-
CTC criteria. Pathology and radiology were centrally reviewed. Results show that in 25 evaluable patients, four PR were
observed (ORR 16%, 95% CI 1–31%). Responses of seven patients were unevaluable. No unexpected toxicity occurred.
Time to progression was 6 months (5–7 months) with a median survival from registration of 9.6 months (95% CI 8–12
months). In conclusion this trial excludes with 90% power a response rate of greater than 30% in patients with malignant
pleural mesothelioma using a combination of gemcitabine and cisplatin at the proposed dose and schedule.
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Malignant pleural mesothelioma (MPM) is an almost always lethal
tumour. The key etiological agent is the prior inhalation of asbestos
dust. Demographic exposure data indicate that its incidence is
expected to further increase in the next decade in most
industrialised countries. The natural history is characterized by a
median survival of nine to 14 months, with less than 5% 5 year-
survivors. Disease extent at diagnosis, performance status and
histological subtype are the main prognostic factors (Curran et
al, 1998; Herndon et al, 1998). Chemotherapy results in a less than
20% response rate and has not yet been shown to improve survival.
Doxorubicin, mitomycin, cisplatin, vinorelbine and high dose
methotrexate are among the drugs showing some activity. Combi-
nation chemotherapy does not consistently appear to provide
better results than single agents, although response rates have been
higher in some studies (Ong and Vogelzang, 1996; Baas et al, 1998;
Steele et al, 2000). The combination of cisplatin and gemcitabine
was reported to be synergistic in terms of cytotoxicity, both in vitro
and in vivo (Peters et al, 1995). Used as single agents response rates
of cisplatin and gemcitabine in malignant mesothelioma have been
reported of 13–14% and 7–24% respectively (Mintzer et al, 1985;
Zidar et al, 1988; Van Meerbeeck et al, 1999; Kindler et al, 2001).
Recently, an objective response rate of 48% has been reported with
the combination of cisplatin and gemcitabine in malignant
mesothelioma in a single institution study (Byrne et al, 1999).
These results prompted us to conduct a multicentre conﬁrmation
phase II study with this combination therapy.
MATERIALS AND METHODS
Patients with histologically conﬁrmed MPM, who had received no
prior chemotherapy were accrued into this study. Tumour exten-
sion was classiﬁed according to the International Mesothelioma
Interest Group (IMIG, 1995) and had to be bidimensionally
measurable in at least one target lesion. Patients with just pleural
effusion were not eligible. Previous intracavitary treatment was
allowed, provided no cytotoxic drugs had been used. Patients
had to be between 18 years and 75 years with a WHO performance
status of 0 to 2, have an adequate haematological (hemoglobin
49.5 g dl
71, granulocyte count 52610
9 l
71, platelet count
5100610
9 l
71), hepatic (bilirubin 425 mmol l
71) and renal
(creatinine clearance 560 ml min
71) function. Prior surgery was
permitted, as well as prior or concomitant radiotherapy of painful
lesions, needle tracks or surgical scars, provided that the indicator
lesions were outside the irradiated ﬁeld. Patients with symptoms or
signs of metastases in the central nervous system and those with a
recent history of body weight loss of 410% were excluded. Writ-
ten informed consent from each patient had to be obtained before
patient entry. Approval by the medical ethical committees of the
participating centres was obtained.
Therapy
Gemcitabine at a dose of 1250 mg m
72 was diluted in normal
saline and administered intravenously over 30 min on days 1 and
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72 was
dissolved in saline and administered intravenously in 3 h on day
1 of each cycle after the gemcitabine administration. Cisplatin infu-
sion was preceded by parenteral administration of a 5HT-3
receptor antagonist and corticosteroids, and the infusion program
contained at least 2 l ﬂuid as hyperhydration. Blood cell counts
were assessed weekly, and liver and renal functions were checked
before each cycle. Treatment cycles were repeated every 21 days,
provided toxic effects were not prohibitive and there was no clin-
ical evidence of tumour progression. The dose of gemcitabine and
cisplatin for subsequent cycles was adjusted according to actual
weight at retreatment. Dose reductions of gemcitabine to
1000 mg m
72 were given in the event of febrile neutropenia, severe
bleeding (NCIC grade IV), ANC nadir 50.5610
9 l
71 or a platelet
nadir 550610
9 l
71 for more than 1 week, or grades 3 or 4 non-
haematological toxicity (excluding nausea, vomiting and alopecia).
However, in the event of an increase in serum creatinine 41.5
times the upper limit of normal, or a creatinine clearance
560 ml min
71, cisplatin was omitted and treatment was contin-
ued with gemcitabine only. The gemcitabine dose on day 8 of a
cycle was reduced to 1000 mg m
72 in the case of a leukocyte count
between 1–2610
9 l
71 or a platelet count between 50–
100610
9 l
71. Gemcitabine was omitted on day 8 in case of a
leukocyte count below 1610
9 l
71 or a platelet count below
50610
9 l
71. Treatment was continued up to six cycles, unless
tumour progression, patient refusal or unacceptable toxicity devel-
oped or the investigator thought that further treatment was not in
patient’s beneﬁt anymore.
Response criteria
Tumour response was assessed with target lesions at baseline, after
every second cycle and at the end of treatment, according to WHO
criteria (Vantongelen, 1994). Target lesions had to be at least
2.5 cm in greatest diameter. Nodular thickening of the pleura
was accepted as a target lesion if the thickening was at least
2 cm in its greatest perpendicular diameter and associated with a
bidimensional lesion. CT-scans were mandatory for evaluation of
intrathoracic lesions. Objective responses had to be conﬁrmed by
two measurements, at least 4 weeks apart. Toxicity was scored
according to the Common Toxicity Criteria of the NCI completed
by the NCIC (1998).
Quality of life and symptom assessment
Symptom assessment was performed using a mesothelioma
checklist, which comprises the most relevant items for mesothe-
lioma of the EORTC QLQ-C30 and the EORTC QLQ-LC13
(Aaronson et al, 1993; Bergman et al, 1994). These items
consisted of a four-point symptom scale for pain, dyspnea, need
to rest, sleep disturbance, weakness, fatigue, pain interfering with
activity and a seven-point scale for overall quality of life (QoL)
and health. A higher score on the scale represents a higher inten-
sity of the symptoms or a lower QoL and health respectively.
The checklist was used as baseline and before each new cycle
of chemotherapy.
Pathology and radiology review
Patient’s suitability for enrolment was determined by the patho-
logic report at the treating institution. Central pathology review
was performed by one of the authors (WJ Mooi) in his capacity
of panel member of the Netherlands Mesothelioma Panel, unless
a pathologist with special expertise in MPM had already
conﬁrmed the diagnosis. Only patients with an unequivocal
histological diagnosis of MPM were considered eligible. Radiolo-
gical response was reviewed by an independent radiologist
(HdB).
Statistical methods
This study was planned according to the Simon (1989) one
sample two stage testing procedure, having type I and type II
error rates of 510% each, in order to differentiate between a
response rate of 10 and 30%. Initial analysis was planned after
16 patients had been treated, and there was a further accrual to
a total of 25 patients if one or more objective responses were seen
in the ﬁrst 16. The regimen would be considered for further
evaluation if more than four objective responses were seen in
evaluable patients, suggesting a true response rate of at least
30%. To compensate for ineligibility, some extra patients were
included. The Kaplan–Meier method was used to estimate overall
survival and time to progression of all eligible patients (Kaplan
and Meier, 1958). Changes in symptoms and quality of life were
evaluated using the general linear model for repeated measure
analysis of variance (Kruskall Wallis H-test).
RESULTS
Between April and December 1999, 32 eligible patients were
included in the study from four institutes in the Netherlands and
Germany. The median interval between diagnosis and inclusion
in the study was 4 months (range 0–24 months). Patient and
tumour characteristics are listed in Table 1.
In total, 127 cycles were administered in 32 patients (range 1–
6). In the 25 evaluable patients (120 cycles), cisplatin was adminis-
tered 117 times with a mean relative dose intensity of 97% (actual
administered dose per week/scheduled dose per week (calculated
on body surface area)6100%). In two patients cisplatin was
stopped after four cycles because of hearing loss and deterioration
of creatinine clearance, respectively. Gemcitabine was administered
234 times with a mean relative dose intensity of 94%. Eight admin-
istrations were not given at day 8 of the cycle: in two patients
chemotherapy was discontinued after the ﬁrst part of the schedule;
four administrations in two patients were omitted because of
thrombocytopenia, one administration because of persisting grade
2 nausea and vomiting and one administration because of fever
of unknown origin.
All eligible patients were evaluated for toxicity. The worst
observed toxicity per patient is shown in Table 2. The median
neutrophil nadir count was 3.1610
9 l
71 and the median platelet
nadir count 143610
9 l
71. In six patients, drug-related toxicity
was the main reason for discontinuation of chemotherapy: four
patients because of grade 3–4 nausea and vomiting, of which three
also showed grade 3 fatigue, one patient because of persisting grade
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Table 1 Patient characteristics
Age (years)
Median 56
Range 42–73
Sex
Male 27
Female 5
Performance status, WHO
05
12 6
21
IMIG-stage
Ib 2
II 2
III 15
IV 13
Histologic subtype
Epithelial 26
Sarcomatous 3
Mixed 3
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grade 3 neurotoxicity with concomitant grade 2 toxicity.
The response evaluation is summarized in Table 3. Seven
patients were unevaluable for response: one patient was lost from
follow up after two cycles; one patient died after one course due
to a tension pneumothorax of the contralateral lung. In ﬁve
instances, chemotherapy was stopped after one cycle because of
toxicity in three patients, refusal in one patient, and one patient
showed a rapid deterioration (dyspnea, fatigue and weight loss)
presumably due to early progression and refused further therapy.
All remaining 25 patients were assessable for response. Among
them, we observed four partial responses (response rate 16%,
95% conﬁdence interval (CI) 1–31%).
The median survival from diagnosis of the eligible patients was
14.6 months (95% CI 12.7–16.4 months) and survival from the
start of treatment was 9.4 months (95% CI 7.3–11.4 months)
(Figure 1). Median time to progression calculated in 25 evaluable
patients was 6.1 months (95% CI 5.7–6.5 months).
After one and two cycles of chemotherapy, QoL-data were
received from 19 (76%) and 18 (72%) of the 25 evaluable patients,
respectively. Compared to baseline, less pain was reported after one
and two cycles of chemotherapy (P50.05). There was no signiﬁ-
cant change in other symptoms or QoL items at baseline
compared to during treatment (data not shown). Compliance to
QoL scoring at further follow-up was below 50%. Due to this
low compliance, it was impossible to make a reliable estimate of
symptoms and QoL beyond two cycles of therapy.
DISCUSSION
In this multicentre study in patients with biopsy proven MPM, we
observed a 16% response rate for the treatment with gemcitabine
and cisplatin. This 3-weekly schedule was given with manageable
toxicity. The observed response rate is in keeping with the one
reported in most cisplatin-based chemotherapy studies in malig-
nant mesothelioma and with the ones reported in studies with
cisplatin and gemcitabine as single agents (Mintzer et al, 1985;
Zidar et al, 1988; Ong and Vogelzang, 1996; Van Meerbeeck et
al, 1999; Kindler et al, 2001). In a single-institution study of
mesothelioma, based on a four weekly regimen of cisplatin and
gemcitabine in malignant mesothelioma, a response rate of 48%
with a median survival of 9.5 months and an estimated 1 year
survival of 41% was observed (Byrne et al, 1999). Recently, a
response rate of 34% was reported in a multicentre study, using
the same regimen (Nowak et al, 2000).
We have analyzed both studies in order to explain the observed
differences in response rate. Of all patient characteristics, only the
distribution of performance status differs signiﬁcantly between
both studies. Since the overall performance status was better in
the present study (WHO 2: 3 vs 29% in the Australian study), this
difference cannot explain the lower response rate in this study. In
contrast to the response rate, median survival in both studies is
similar and comparable to the one observed in several EORTC
phase II studies (Curran et al, 1998), further suggesting a compar-
able patient selection.
As mentioned, Byrne et al (1999) used a 28-day cycle with
gemcitabine on days 1, 8 and 15, whereas we used a 21-day cycle.
The planned dose in mg m
72 per week of a chemotherapy cycle in
these schedules, was in the present study slightly higher for both
agents (cisplatin 26 vs 24 mg m
72 per week and gemcitabine 785
vs 619 mg m
72 per week). The administered dose calculated in
mg m
72 per week was also slightly higher in the present study
for both agents. In patients with non-small cell lung cancer treated
with cisplatin and gemcitabine, a similar response rate with less
toxicity was observed with a 3-week schedule compared to a 4-
week schedule (Cardenal et al, 1999). So, schedule differences are
not likely to explain the differences in response rate.
Both studies differ in the method to assess tumour response. In
the present study, partial response was deﬁned as a 50% reduction
in the sum of the product of bidimensionally measurable lesions,
whereas Byrne et al (1999) also included a 30% decrease in the
sum of unidimensional measurements. Although both studies
required a conﬁrmed response, it is unclear whether these were
independently reviewed in the Australian series. We re-evaluated
the patients from one centre with the latter unidimensional criteria.
From seven patients with stable disease according to the WHO
criteria, we found one additional conﬁrmed partial response with
these unidimensional criteria. For rounded tumours, a 30% unidi-
mensional reduction equals a 50% bidimensional reduction and a
65% tumour volume reduction. In mesothelioma, which often
grows in the plane of the pleural surface, a unidimensional reduc-
tion in pleural thickness does not necessarily coincide with a
reduction in other dimensions. If the pleural surface affected is
unchanged, a unidimensional reduction of pleural thickness of
C
l
i
n
i
c
a
l
Table 2 Worst chemotherapy-related toxicity in all eligible patients
(n=32)
Grades 1–2 Grade 3 Grade 4
Leukocytopenia 21 2 0
Thrombocytopenia 7 4 0
Anaemia 14 4 0
Nausea 24 3 2
Vomiting 21 2 2
Fatigue 24 2 0
Anorexia 10 2 0
Diarrhoea 3 1 0
Neurotoxicity 17 1 0
Cardiovascular 0 1 0
Table 3 Response evaluation
n %
Eligible patients 32 100
Not evaluable 7 22
Evaluable 25 78
Response 25 100
CR 0 0
PR 4 16
SD 18 72
PD 3 12
Cumulative proportion alive
1.0
0.8
0.6
0.4
0.2
0.0
0                                            10                                           20
Months
Censored
Figure 1 Survival from start of treatment in 32 eligible patients.
Gemcitabine and cisplatin in mesothelioma
JMW van Haarst et al
344
British Journal of Cancer (2002) 86(3), 342–345 ã 2002 The Cancer Research Campaign30% only reﬂects a 30% reduction in tumour volume. At ﬁrst
glance Byrne’s method seems to comply with the recently intro-
duced RECIST criteria (Therasse et al, 2000). However, the
pleural thickness usually reﬂects the smallest diameter, whereas in
the RECIST criteria the longest diameter is required.
A ﬁnal factor that may possibly lead to differences in response
rates, is a regional difference in biological behaviour of MPM or
its sensitivity to an antineoplastic agent due to environmental or
genetic factors (Linnainmaa et al, 1997). There are at present, no
data to support this pharmacogenetic heterogeneity in human
mesothelioma patients.
Our data suggest that QoL and symptom severity were not
adversely affected by two cycles of chemotherapy and that pain
control improved. The latter might either be an effect of the
chemotherapy itself or reﬂect a more intensive pharmacological
pain treatment. The value of measuring QoL in a phase II trial
can be disputed. However, it allows a crude estimate with each
patient being his/her own control. Symptomatic improvement
has been observed more frequently than objective response in
mesothelioma and other cancer patients (Steele et al, 2000). This
has to be considered when discussing the likely palliative beneﬁt
to an individual patient. In conclusion, this trial excludes at 90%
power a response rate of greater than 30% in patients with
MPM using a combination treatment of cisplatin and gemcitabine
at the proposed dose and schedule. Hence, from our data we
cannot recommend this combination therapy as a standard therapy
for MPM.
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